Inge Marie Svane

54PUBLICATIONS
236CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (54)

|Aug 31, 2026
Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

|Aug 20, 2026
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

|Jul 23, 2026
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.

|Jun 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

|May 18, 2026
Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

|Mar 05, 2026
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.

Rikke Boedker Holmstroem, Ane Soegaard Teisner, Mark Wilhelmus Dirk Sweep

Pageof 9

Frequent Collaborators

27 joint publications

Marco Donia

12 joint publications

Eva Ellebaek

9 joint publications

Mads Hald Andersen

9 joint publications

Özcan Met